- PR Newswire•19 hours ago
Upper respiratory infections are among the most common reasons for outpatient visits in the United States and worldwide.2,3 Early symptoms for a wide variety of viral and bacterial respiratory infections are often clinically indistinguishable, yet treatment is different depending on the cause of infection, highlighting the importance of accurate diagnostic tests like Xpert Xpress Flu/RSV. With this development, hospitals and clinics can reliably diagnose influenza and respiratory syncytial virus (RSV) infection in 30 minutes or less. Xpert Xpress Flu/RSV is twice as fast as its predecessor, Xpert Flu/RSV XC, but has comparable performance characteristics. The new assay features a novel design, which employs multiple targets for each virus. The built-in redundancy provides very high test sensitivity, avoiding the impact of seasonal drift that has been a problem historically with molecular tests, while maintaining high specificity.
- PR Newswire•4 days agoCepheid Announces Receipt of Required Regulatory Clearances in Proposed Acquisition by Danaher Corporation
SUNNYVALE, Calif., Oct. 24, 2016 /PRNewswire/ -- Cepheid (CPHD) today announced that antitrust clearances have been received or the requisite waiting periods have expired, as applicable, in the United States, Germany, Austria and South Africa, which comprise all of the governmental approvals required as a closing condition pursuant to the merger agreement executed in connection with the proposed acquisition of Cepheid by Danaher Corporation. As previously disclosed, on September 2, 2016, Cepheid, Danaher Corporation ("Parent"), and Copper Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), entered into an Agreement and Plan of Merger ("Merger Agreement"). Pursuant to the terms of the Merger Agreement, and subject to the conditions thereof, Merger Sub will merge with and into Cepheid, and Cepheid will become a wholly-owned subsidiary of Parent (the "Merger").
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||52.92 - 52.94|
|52wk Range||25.09 - 53.91|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-77.48|
|Avg Vol (3m)||2,080,450|
|Dividend & Yield||N/A (N/A)|